Mizuho maintains Outperform on Biogen, lowers target to $221

0 min read Updated on 15 Jun 2026, 11:26 PM

Reviewed by

Radhika SScanX News Team

AI Summary

Mizuho analyst Salim Syed maintained an Outperform rating on Biogen (NASDAQ: BIIB) but lowered the price target from $236 to $221, reflecting a revised valuation outlook.

*this image is generated using AI for illustrative purposes only.

Mizuho analyst Salim Syed has maintained an Outperform rating on Biogen (NASDAQ: BIIB) while adjusting the valuation expectations for the stock. The firm lowered the price target to $221, down from the previous $236.

The revision reflects a reassessment of the company's outlook despite the continued positive stance on its performance. The Outperform rating indicates that the stock is still expected to perform better than the broader market average.

Rating and Target Details

Metric	Value
Rating	Outperform
Previous Price Target	$236
New Price Target	$221
Ticker	NASDAQ: BIIB

What specific factors led Mizuho to lower the price target while maintaining an Outperform rating?

How might Biogen's upcoming product pipeline influence the stock's performance in the next year?

What are the potential risks to Biogen's growth that could justify further downward revisions?

Read Next Article

Biogen pipeline readouts could offset base decline

1 min read Updated on 08 Jun 2026, 11:23 PM

Reviewed by

Radhika SScanX News Team

Add as a preferred
source on Google

AI Summary

Needham upgraded Biogen Inc. to Buy with a price target of $255, citing eight Phase III readouts through 2029. Analyst Ami Fadia projects five growth products could offset base business decline, driving a five-year revenue CAGR of around 2%. Positive pipeline results could generate more than $7 billion in combined peak sales.

*this image is generated using AI for illustrative purposes only.

Biogen Inc. is entering a period of significant pipeline optionality that could counterbalance a declining base business, according to a new report from Needham. Analyst Ami Fadia upgraded the stock rating from Hold to Buy and established a price target of $255, highlighting eight Phase III readouts scheduled through 2029 as a key catalyst for future growth.

The analyst projects that five growth products and two assets from the Apellis deal, which closed in May, could "more than offset the base business declining in the mid-single digits." This combination is expected to drive a five-year revenue compounded annual growth rate (CAGR) of around 2%. If the pipeline yields positive results, Fadia estimates it could generate more than $7 billion in combined peak sales, potentially lifting the five-year CAGR to the mid-single digit range.

Key growth drivers identified include an improving trajectory for Leqembi and the stabilization of Spinraza following the approval of a high dose in March. Additionally, the combined performance of Syfovre and Empaveli is anticipated to deliver mid-to-high teens growth.

Upcoming Catalysts

The next significant data points expected are the Phase III readouts for Litifilimab. The trial for systemic lupus erythematosus (SLE) is anticipated in the fourth quarter of 2026, while the readout for cutaneous lupus erythematosus (CLE) is expected in mid-2027. Fadia estimates peak sales for Litifilimab to exceed $2 billion.

Management expects to de-lever following the Apellis deal by the end of 2027. This financial strategy is intended to preserve strategic flexibility, allowing the company to continue pursuing business development opportunities.

Biogen shares were down 0.34% at $194.68 at the time of publication on Monday.

How will Biogen prioritize capital allocation between de-leveraging and new business development opportunities before the 2027 deadline?

What specific market share risks does Leqembi face from competing Alzheimer's treatments that could impact the projected growth trajectory?

Could the anticipated mid-to-high teens growth from Syfovre and Empaveli be sustained if safety concerns or competitive entrants emerge in the complement disease market?